Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
285 stopped studies mapped to Acute Lymphoblastic Leukemia and descendants · 88% state a reason
Over the 285 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03066466 | Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD… | Phase 3 | withdrawn | Feb 28, 2017 | Loyola University | No participants were enrolled | Enrollment / accrual |
| NCT01685411 | Busulfan and Cyclophosphamide Followed By ALLO BMT | N/A | terminated | Sep 14, 2012 | Masonic Cancer Center, University of Minnesota | not stated | Not stated |
| NCT03094611 | Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive… | Phase 2 | terminated | Mar 29, 2017 | M.D. Anderson Cancer Center | the study was closed early due to competing trials | Other (stated, no rule matched) |
| NCT00439296 | ABT-751 With Chemotherapy for Relapsed Pediatric ALL | Phase 1 / Phase 2 | terminated | Feb 23, 2007 | Therapeutic Advances in Childhood Leukemia Consortium | The study was stopped due to poor accrual and lack of funding. | Enrollment / accrual |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Phase 2 | withdrawn | Nov 14, 2018 | City of Hope Medical Center | RSS recommendation | Other (stated, no rule matched) |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | Phase 1 | terminated | Feb 21, 2011 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT04094766 | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R… | Phase 1 | withdrawn | Sep 19, 2019 | Second Affiliated Hospital of Xi'an Jiaotong University | Production plan adjustment | Other (stated, no rule matched) |
| NCT01483690 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | Phase 1 / Phase 2 | terminated | Dec 1, 2011 | Therapeutic Advances in Childhood Leukemia Consortium | Toxicity | Safety / toxicity |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | Phase 1 | terminated | Apr 25, 2016 | Washington University School of Medicine | Toxicity. Only enrolled patients in phase I portion of trial. | Safety / toxicity |
| NCT00981799 | Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | Phase 1 / Phase 2 | terminated | Sep 22, 2009 | Therapeutic Advances in Childhood Leukemia Consortium | Slow accrual rate | Enrollment / accrual |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT03888534 | Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute… | Phase 1 | withdrawn | Mar 25, 2019 | Millennium Pharmaceuticals, Inc. | Business decision (no safety or efficacy concerns) | Safety / toxicity |
| NCT01658007 | Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute…(SIR-MO-1101) | Early Phase 1 | terminated | Aug 6, 2012 | Children's Hospital Medical Center, Cincinnati | Slow Accrual | Enrollment / accrual |
| NCT03985215 | The Value of Follow-Up After Childhood Acute Lymphoblastic Leukaemia in Denmark - Family… | — | withdrawn | Jun 13, 2019 | University of Aarhus | Overlapping with another danish questionnaire study | Other (stated, no rule matched) |
| NCT03515200 | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic… | Phase 1 | terminated | May 3, 2018 | St. Jude Children's Research Hospital | Due to departure of PI from St. Jude | Other (stated, no rule matched) |
| NCT02767934 | Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic… | Phase 2 | terminated | May 11, 2016 | University of Washington | Terminated due to lack of efficacy | Efficacy / futility |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After… | Phase 1 | terminated | May 7, 2008 | University of Pennsylvania | Insufficient funds | Funding |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood… | Phase 1 | withdrawn | Jan 16, 2019 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT00983528 | Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | terminated | Sep 24, 2009 | University of California, San Diego | Support withdrawn due to slow accrual | Enrollment / accrual |
| NCT01551043 | Allo CART-19 Protocol | Phase 1 | terminated | Mar 12, 2012 | University of Pennsylvania | Administrative Reasons | Other (stated, no rule matched) |
| NCT03628053 | Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory…(OBERON) | Phase 3 | withdrawn | Aug 14, 2018 | Novartis Pharmaceuticals | Novartis is no longer pursuing this study because of planned investigation of novel CAR-T therapies… | Other (stated, no rule matched) |
| NCT02535364 | Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic…(ROCKET) | Phase 2 | terminated | Aug 28, 2015 | Juno Therapeutics, a Subsidiary of Celgene | Safety reasons | Safety / toxicity |
| NCT02349178 | Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT | Phase 2 | terminated | Jan 28, 2015 | Medical College of Wisconsin | Low accrual | Enrollment / accrual |
| NCT02588092 | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid… | Phase 1 | terminated | Oct 27, 2015 | ADC Therapeutics S.A. | Slow enrollment | Enrollment / accrual |
| NCT02819804 | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia… | Phase 1 | terminated | Jun 30, 2016 | Northwestern University | Due to funding and accrual issues | Enrollment / accrual |
| NCT02404220 | Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With… | Phase 1 / Phase 2 | terminated | Mar 31, 2015 | Gilead Sciences | not stated | Not stated |
| NCT02435550 | iCare for Cancer Patients | N/A | terminated | May 6, 2015 | University of Florida | Halted due to funding issues. | Funding |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells… | Phase 1 | terminated | Sep 4, 2014 | National Heart, Lung, and Blood Institute (NHLBI) | not stated | Not stated |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or… | Phase 2 | terminated | Jun 22, 2017 | Fred Hutchinson Cancer Center | Terminated because of slow recruitment and lack of funding support | Enrollment / accrual |
| NCT01747499 | Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | Phase 1 / Phase 2 | terminated | Dec 11, 2012 | Washington University School of Medicine | Enrolling 8 more patients would be statistically unlikely that the primary endpoint would be… | Enrollment / accrual |
| NCT01408160 | Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Aug 3, 2011 | Albert Einstein College of Medicine | not stated | Not stated |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | Phase 2 | terminated | Jan 13, 2006 | Masonic Cancer Center, University of Minnesota | Drug was not available. | Other (stated, no rule matched) |
| NCT02535806 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children… | Phase 2 | terminated | Aug 31, 2015 | Children's Mercy Hospital Kansas City | Funding source discontinued | Funding |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01974479 | Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage… | Phase 1 | suspended | Nov 1, 2013 | National University Health System, Singapore | Suspended for an interim review of (CAR) CD19 research strategy for the treatment of CD19 positive… | Sponsor / business decision |
| NCT02518750 | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or… | Phase 2 | terminated | Aug 10, 2015 | St. Jude Children's Research Hospital | Due to slow accrual | Enrollment / accrual |
| NCT03187691 | Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal… | Phase 2 | withdrawn | Jun 15, 2017 | Matinas BioPharma Nanotechnologies, Inc. | Protocol redundancy | Other (stated, no rule matched) |
| NCT00928200 | Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND… | Phase 1 | terminated | Jun 25, 2009 | Therapeutic Advances in Childhood Leukemia Consortium | Study was terminated due to lack of accrual. | Enrollment / accrual |
| NCT02989675 | SugarFACT - Sugar Requirements For African Children Trial | N/A | terminated | Dec 12, 2016 | Helena Hildenwall | not stated | Not stated |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory… | Phase 1 | terminated | May 27, 2015 | Janssen Research & Development, LLC | Recent advances in the treatment of B cell malignancies resulting in new treatments being approved… | Other (stated, no rule matched) |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin… | Phase 2 | withdrawn | Sep 2, 2015 | University of Washington | Drugs unavailable | Other (stated, no rule matched) |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic… | Phase 1 | terminated | Apr 5, 2016 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT02632903 | Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in… | Phase 2 | withdrawn | Dec 17, 2015 | Children's Hospital of Eastern Ontario | While the clinical need for and the scientific merit remain valid, this regulated drug trial was… | Funding |
| NCT00900445 | Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk… | — | withdrawn | May 12, 2009 | Children's Oncology Group | not stated | Not stated |
| NCT01037764 | Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic…(AHCTALL) | Phase 2 | terminated | Dec 23, 2009 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT01761682 | Acute Lymphoblastic Leukemia Registry at Asan Medical Center | — | terminated | Jan 7, 2013 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT02428517 | Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia…(ATLAS2015) | — | terminated | Apr 28, 2015 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood… | Phase 2 | terminated | Dec 10, 2012 | Weill Medical College of Cornell University | Slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Apr 27, 2021source: clinicaltrials